PROMISS
DIAGNOSTICS

ADVANCING OVARIAN CANCER DIAGNOSIS

OVARIAN CANCER

LEADING CAUSE OF ALL GYNECOLOGICAL CANCER DEATHS

65%
Diagnosed stage III, IV

54%
Die within five years

BECAUSE ...

Lack of screening test

Poor performance of diagnostic tests

Lack of accessibility to specialists

THE CURRENT STANDARD OF CARE IS FAILING WOMEN

STANDARD OF CARE BASED ON ACOG GUIDELINES

CA125 Shortcomings

CA-125 is non-specific & results in high false negatives

60% false positive

34k unneeded major surgeries

PELVIC MASSES ARE COMMON

MISDIAGNOSIS LEADS TO OVERTREATMENT

75-90%
Benign Masses

|		
Pelvic mass diseases	20M	Common Symptoms, Endometriosis, Functional Cysts
Pelvic masses	750K	Physiologic Cyst Benign Mass — Initial market
Pelvic masses to surgery	350k	
Ovarian cancer	22k	
Ovarian cancer deaths	15k	

PROMISS ADVANCES THE STANDARD OF CARE

Diagnostics Tool establishes the presence and absence of ovarian cancer

PROMISS ADVANCES EARLY OVARIAN CANCER DETECTION

MULTI-ANALYTE ALGORITHMIC ANALYSIS (MAAA) REDUCES FALSE NEGATIVES AND FALSE POSITIVES

Chemistry Markers (FDA cleared)

Machine Learning

Cloud-based algorithm

Clinical Data

ANALYZE

PROMISS combines markers & data into a single score

PROMISS SCORE

HIGH RISK of malignancy

LOW RISK of malignancy

Technology developed at University of Wisconsin-Madison

OPERATIONAL BUSINESS MODEL IS STREAMLINED

PROVEN CLOUD COMPUTING MODEL POSITIONS PROMISS FOR SCALABILITY

Cloud-based algorithm

Report to **CLINICIANS**

CLINICIANS order PROMISS test

COMMON BLODD values and patient data are sent to PROMISS Dx

PROMISS algorithm analyzes data

PROMISS bills **PAYERS**

PILOT study on **MAYO** Cloud Platform **VALIDATED** PROMISS Operational Model

MAYO CLINIC PLATFORM

Payment rates for existing CPT code is $897 (CMS) and an average of $1,200 (private payers)

PROMISS IS SUPERIOR TO STANDARD OF CARE

PROMISS INNOVATION PROVIDES CLINICAL AND ECONOMIC VALUES TO IMPROVE PATIENT OUTCOMES

|	CA125	ROMA	OVA1	PROMISS	
Sensitivity (%)	50's	70's	80's	90	Clinical Performance
Specificity (%)	50's	40-70	<40	63	
Type of tests	Immunoassay	Immunoassay	Immunoassay	Chemistry*	Economics
Simplicity/Accessibility/Scalability	Moderate	Low	Low	High	
Payer reimbursement/test ($)	50	450	1,200	750**	

* **Employs existing CHEMISTRY tests; in contrast, IMMUNOASSAY tests are more complex, labor intensive, lower throughput, and more expensive**

** **Higher margin than other tests due to new use of existing clinical data and chemistry biomarkers; estimated payment**

EXPANSION BEYOND DIAGNOSTICS

PROMISS SOLVES AT LEAST THREE UNMET NEEDS IN OVARIAN CANCER DIAGNOSIS

LARGE MARKET AND SIGNIFICANT UNMET NEED

PROMISS SOLVES AT LEAST <u>THREE</u> UNMET NEEDS IN OVARIAN CANCER DIAGNOSIS

> **> $2.4B**

Total Addressable Market in USA

>$560M

Diagnostic Tool

(> 750k tests)

> $600M

Active Surveillance

(> 2M tests)

> $1.3B

RISK STRATIFICATION

(> 20M tests)

LARGE POTENTIAL EXPANDED OPPORTUNITY
outside USA market

PROMISS DIAGNOSTICS

EXPERIENCED AND MOTIVATED MANAGEMENT TEAM

Management Team

Jalal Sulaiman
MS, MSEE, BB6σ, MBA
CEO/Co-founder
15 years of strategic planning and organization management in healthcare industry
MBA, University of Chicago
Received GE President Award

Roa Qato
MD, OB/GYN
Chief Medical Officer/Co-founder
>15 years of clinical experience in academic and private practice
Best Surgeon for PGY-3
Winner of the Jerome J. Hoffman Award

R&D Team

Yolanda Hagar
PhD, Consultant
Chief Data Scientist
Experienced in protein biomarker discovery and clinical diagnostics industry

PROMISS
DIAGNOSTICS

EXPERIENCED ADVISORY BOARD

Stephen Coutts, PhD, MBA
Business/Scientific Advisor
43 years in life science, seasoned entrepreneur
Product development strategy

Ellen Rudnick, MBA
Business Advisor
> 20 years in healthcare industry
Strong network in life science, Health Systems and VCs

Ian Gunsolus, PhD
Scientific Advisor;
Lab Chemistry Advisor
Medical Laboratory Scientific Director at HealthPartners;
Board certified in clinical chemistry

Lisa Anselmino, PhD
Business Development Advisor
30 years in dx industry
Business and partnership development
Strong network in diagnostics

John Jedziniak, MBA
Technology Advisor
>20 years experience in medical device, AI, EMR and data connectivity

Ilke Panzer, MSE
Business Strategy Advisor
>30 years experience in diagnostics;
CEO Greiner Bio-One International
Former SVP of diagnostic laboratories at BloodCenter

ABBOTT Alere **Baxter** MEDICAL COLLEGE OF WISCONSIN greiner BIO-ONE

PROMISS DIAGNOSTICS

BOARD OF DIRECTORS

Michael Partsch, MBA
Board Chair
Chief Venture Officer at WARF
30 years in healthcare industry
Former roles:
- Serial life science entrepreneur
- Founder/CEO of HanydyLab, $275M exit
- 4 venture funds , +$160M raised

Douglas Stafford, PhD, MS
Board Member
35 years in healthcare industry
Former roles:
- Founded 5 companies, 2 IPOs
- Raised $75M in capital
- CEO, Ophidian Pharmaceuticals
- Director at Baxter Healthcare

Steven Kuemmerle, PhD
Board Member
30 years in healthcare industry
Former roles at Abbott:
- Head of Venture Investments
- Director of Global Licensing
- Director of Diagnostics R&D

Jalal Sulaiman, MS, MBA
Board Member, President
Decade of strategic planning
and organization
management in healthcare
industry

Michael Harrison, PhD, MD
Board Secretary
Business Development Manager
at BioForward

$5.0M SERIES A FUNDING to LAUNCH

FDA 510k clearance

Conduct retrospective clinical trials of 775 patients at three sites

Market Development

Educational marketing campaign; CMS and private insurance coverage

Product development

Implement business operating model using cloud computing platform

Seed investment history: $620k
(Northwestern Mutual & WARF)

Series A commitments: >$2.0M

WARF
Wisconsin Alumni Research Foundation

Northwestern Mutual
Cream City Venture Capital

PROMISS TECHNOLOGY BASIS FOR COMPETITION

Performance Superiority

PROMISS outperforms standard of care (CA125) especially for pre-menopausal women and has high positive predictive value

Simplicity & Scalability

Rapid penetration due to use of existing standard chemistry systems.
No assay development costs
No user CAPX investment

Multiple Clinical Utility

Clinical applications in OC diagnostics including diagnostic aid, monitoring and screening

Non-invasive test with high sensitivity for early detection

Patented technology to address large unmet needs

Fast path to product approval/launch based on existing clinical POC; exit opportunities with high ROI

CONTACT

PROMISS
DIAGNOSTICS

JALAL SULAIMAN

President and CEO

Jalal.sulaiman@promissdx.com

(608) 354-1648